We were glad to take part in BioHK2026 at the Hong Kong Convention and Exhibition Centre last week, and to meet many friends and professionals from the biotech, healthcare and life sciences sectors.

Our Yolanda Wang moderated the Patent Session panel, "Protect & Resolve: The Biotech IP Playbook for Going Global," on September 12. The discussion covered practical points for biotech companies expanding internationally, including IP planning, risk management and dispute resolution.

Many thanks to the organizers, fellow panelists and everyone who joined the discussion. It was a pleasure to be part of the programme.

As biotech companies continue to look beyond their home markets, early and practical IP strategy will remain an important part of business growth.

我们的过去活动

Recommended Insights

No % homology? How to craft allowable claim scope around sequences to comply with China’s strict written description requirements

2018年11月23日
Since 2010, the Patent Re-examination Board (PRB) has published the top 10 patent invalidation cases of the year in April of each year. The selection criteria are high social concern, significant impact on the related industry, or involve difficult legal issues and important examination criteria. Below is one of the top 10 cases that discusses […]

China’s Newest Examination Guidelines: Novelty and Inventive Step for Compounds (Part II)

2021年4月29日
This is Part II of a three-part series summarizing the Examination Guidelines that were released by the CNIPA on January 15, 2021, one year to the date of Phase 1 of the US and China Economic and Trade Agreement. That agreement included specific provisions where China "shall permit pharmaceutical patent applicants to rely on supplemental […]

China Finally Clamps Down on Facial Recognition Technology

2021年8月24日
Snippets of Court Cases, Provisions, and Key Observations about China’s IP Landscape Around the end of July 2021, the Supreme People’s Court issued a new Provision concerning the application of law about a super-hot technology, facial recognition. This Provision is a legal explanation from the SPC explaining how the law should be applied or interpreted […]

The Latest on Post-Filing Data in China’s Patent Law

2020年4月29日
Post-filing data can sometimes be the crucial difference between a patent allowance and a final rejection. The reasons are endless why important data may not have been included in the original patent application as filed. Time and budget may have been insufficient to generate data over the full scope of the claims at the time […]
Top crossarrow-right